William Blair Expects Lower Earnings for ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Equities research analysts at William Blair lowered their Q1 2025 EPS estimates for ARS Pharmaceuticals in a report issued on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($0.35) per share for the quarter, down from their previous forecast of ($0.25). William Blair has a “Outperform” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($0.14) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.56. The company had revenue of $86.58 million for the quarter, compared to analysts’ expectations of $15.46 million.

A number of other equities analysts have also recently issued reports on the stock. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective on the stock. Scotiabank began coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Raymond James boosted their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Leerink Partners raised their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $31.00.

ARS Pharmaceuticals Stock Performance

Shares of ARS Pharmaceuticals stock opened at $13.15 on Monday. ARS Pharmaceuticals has a 52-week low of $7.55 and a 52-week high of $18.51. The company’s 50 day moving average price is $12.13 and its 200-day moving average price is $13.07. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -25.78 and a beta of 1.03.

Hedge Funds Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC grew its stake in shares of ARS Pharmaceuticals by 189.7% in the 3rd quarter. Barclays PLC now owns 111,666 shares of the company’s stock worth $1,618,000 after buying an additional 73,127 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of ARS Pharmaceuticals by 93.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company’s stock worth $3,631,000 after acquiring an additional 165,950 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of ARS Pharmaceuticals by 766.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock valued at $3,401,000 after acquiring an additional 207,456 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in shares of ARS Pharmaceuticals in the 4th quarter worth about $4,469,000. Finally, State Street Corp raised its position in shares of ARS Pharmaceuticals by 10.4% in the 3rd quarter. State Street Corp now owns 2,049,542 shares of the company’s stock worth $29,718,000 after purchasing an additional 193,321 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

Insider Activity

In related news, Director Laura Shawver sold 49,600 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $11.21, for a total value of $556,016.00. Following the completion of the transaction, the director now directly owns 210,346 shares in the company, valued at $2,357,978.66. This trade represents a 19.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now directly owns 7,696 shares of the company’s stock, valued at approximately $107,744. This trade represents a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 159,600 shares of company stock worth $1,866,516 in the last quarter. 40.10% of the stock is owned by company insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.